Form 4: Monopar Director Reports Indirect Stock Disposition

Diane Hendricks, a Director and 10% owner of Monopar Therapeutics, reported an indirect disposition of 43,499 shares of common stock with no pecuniary interest.

Summary

• Diane Hendricks, identified as a Director and 10% Owner of Monopar Therapeutics [MNPR], filed a Form 4.
• The filing indicates that Ms. Hendricks is no longer subject to Section 16 obligations, despite her listed roles as Director and 10% Owner.
• The reported transaction date is December 16, 2025, which is a future date relative to the filing date.
• The transaction involves an indirect disposition of 43,499 shares of Monopar Therapeutics Common Stock.
• This disposition is a pro rata distribution by Gem Pharmaceuticals, LLC to its members, in which Ms. Hendricks disclaims any pecuniary interest.
• Following this transaction, Ms. Hendricks indirectly beneficially owns 567,580 shares through Gem/Pharma and an additional 93,750 shares through DMH Business LLC.

Sentiment

Score: 5

Explanation: Neutral. The filing is a routine regulatory disclosure of an insider transaction. The disposition is indirect and without pecuniary interest for the reporting person, which generally does not signal negative insider sentiment. However, the unusual future transaction date and internal inconsistency regarding Section 16 status introduce minor complexities.

Positives

• The reported disposition is an indirect transaction where the reporting person, Diane Hendricks, explicitly disclaims any pecuniary interest, indicating it is not a direct sale for personal gain.

Negatives

• The filing contains an internal inconsistency, stating Diane Hendricks is both a Director and 10% Owner (implying Section 16 applicability) while also checking the box indicating she is no longer subject to Section 16.
• The transaction date of December 16, 2025, is in the future relative to the filing date, which is unusual for a Form 4 reporting a 'change in beneficial ownership'.

Risks

• Potential for misinterpretation by investors due to the unusual future transaction date and the contradictory statement regarding the reporting person's Section 16 status.
• The complexity of indirect ownership structures involving multiple entities (Gem Pharmaceuticals, Pharma Investments LLC, DMH Business LLC) may obscure the true nature of beneficial ownership and control.

Future Outlook

This Form 4 filing does not provide any forward-looking statements or guidance regarding Monopar Therapeutics' future operations or financial performance.

Management Comments

• Ms. Hendricks disclaims beneficial ownership of the 93,750 shares held by DMH Business LLC, except to the extent of her pecuniary interest therein.
• The managers of Gem and the controlling shareholders of Pharma each disclaim ownership of the shares of common stock owned by Gem, except to the extent of their pecuniary interest therein.

Industry Context

Form 4 filings are standard regulatory disclosures for reporting changes in beneficial ownership by company insiders. This specific filing details an indirect transaction, which is less common than direct purchases or sales, and involves complex ownership structures typical of certain investment vehicles.

Comparison to Industry Standards

• Not applicable. This filing reports an insider transaction and does not contain operational or financial results for comparison to industry benchmarks or competitors.

Related Party Transactions

• The disposition involves Gem Pharmaceuticals, LLC, where Pharma Investments LLC (controlled by Ms. Hendricks) owns a controlling share, indicating a related party transaction in the context of beneficial ownership.
• Ms. Hendricks' indirect ownership of 93,750 shares through DMH Business LLC, where she is a manager, also represents a related party relationship.

Stakeholder Impact

• Shareholders: May note the change in indirect ownership structure and the reporting person's stated status of no longer being subject to Section 16, which could affect future transparency of minor transactions.
• Regulatory Authorities: The internal inconsistencies regarding Section 16 status and the future transaction date might warrant closer scrutiny by the SEC for compliance.

Next Steps

• The reporting person, Diane Hendricks, has checked the box indicating she is no longer subject to Section 16, which may imply a reduction in future Form 4 filing obligations for certain types of transactions.

Key Dates

Keywords

Monopar Therapeutics, MNPR, Diane Hendricks, Insider Transaction, Form 4, Beneficial Ownership, Stock Disposition, Director, 10% Owner, Corporate Governance